Vaccines

STATEMENT FROM THE WHO-UNAIDS HIV VACCINE ADVISORY COMMITTEE (VAC) ON NIH/HVTN/MERCK RELEASE OF NEW DATA FROM THE ANALYSIS OF STEP TRIAL RESULTS

12 November 2007

On 7 November 2007 at the HIV Vaccine Trials Network (HVTN) meeting in Seattle, NIH, HVTN and Merck released updated results based on post hoc analysis of data from a large-scale STEP trial with a Merck candidate vaccine (MRK-Ad5).

Joint WHO/ UNAIDS/ UNICEF statement on use of Cotrimoxazole as prophylaxis in HIV exposed and HIV infected children

02 March 2007

WHO, UNAIDS and UNICEF, guided by recent evidence, have agreed to modify as an interim the current recommendations (1) for cotrimoxazole prophylaxis in children. This is based upon recent trial data from Zambia (2).

UNAIDS welcomes new partnership to accelerate global HIV vaccine research and development efforts

20 February 2007

The Joint United Nations Programme on HIV/AIDS (UNAIDS) welcomes a new collaborative initiative between the Government of Canada and the Bill & Melinda Gates Foundation to accelerate HIV vaccine research and development. The partnership entitled the ‘Canadian HIV Vaccine Initiative’ (CHVI) will contribute to the global effort to develop safe, effective, affordable and globally accessible HIV vaccines.

Health leaders welcome infectious disease focus at G8

03 July 2006

In advance of the G8 summit, the

Africa takes action to overcome challenges for HIV vaccine development

17 October 2005

A ministerial level meeting is set to review the current status of HIV vaccine research and development, as well as a range of challenges concerning Africa's active participation and contribution to this area, in collaboration with various stakeholders and partners.

HIV vaccine global partners strengthen collaboration to speed up progress

07 February 2005

As new developments in the search for an HIV vaccine take place, vaccine researchers from around the world are joining forces to accelerate progress towards an effective and safe HIV vaccine, with the full and equal involvement of countries most affected by the AIDS epidemic.

A globally effective HIV vaccine requires greater participation of women and adolescents in clinical trials

31 August 2004

Greater participation of women and adolescents is needed in HIV vaccine clinical trials, according to a group of international experts, who attended a consultation on HIV vaccine trials in Lausanne, Switzerland, from 26-28 August.

HIV/AIDS treatment, microbicide and vaccine advocates release plan of action and joint statement of commitment

12 July 2004

AIDS activists from around the world, representing different movements, today called for concerted action aimed at ramping up HIV/AIDS health care services in low and middle-income countries.

WHO/UNAIDS welcomes G-8 endorsement of the global HIV vaccine enterprise

11 June 2004

The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) today welcomed the G-8's endorsement of the Global HIV Vaccine Enterprise, a virtual consortium proposed by an international group of scientists that is being established to accelerate HIV vaccine development.

No time to lose in the search for an HIV vaccine

16 May 2013


GENEVA, 18 May 2013—The Joint United Nations Programme on HIV/AIDS (UNAIDS) joins partners and allies around the world in recognizing World AIDS Vaccine Day. 

Developing an HIV vaccine is one of the greatest scientific challenges the world faces—and one of the most important. While encouraging progress has been made in the AIDS response, getting to zero new HIV infections will ultimately require a safe and highly effective HIV vaccine.

The recent news that a potential vaccine candidate was found ineffective in a large clinical trial highlights the magnitude of the task. However, evidence shows that a vaccine is possible. One candidate has already been shown to be partially effective (the RV144 trial, reported in 2009),   and a multinational research collaboration is investigating ways to improve upon it. In the laboratory, exciting new discoveries may soon lead to the development of entirely different types of vaccines.

“Despite the formidable challenge of finding a vaccine for a complex virus like HIV, there is today a more systematic and concerted scientific effort than ever before,” said Michel Sidibé, Executive Director of UNAIDS. “Sustained funding for research to find a vaccine for HIV is essential. With almost five new infections every minute, there is no time to lose.”

While the scientific challenges are great, they are being overcome due to the commitment and hard work of researchers, study participants, and affected communities. An effective HIV vaccine is only possible with continued support and investment in this critical work.


Contact

UNAIDS Geneva
Sophie Barton-Knott
tel. +41 22 791 1697
bartonknotts@unaids.org

Pages